Silverstar Joins Mammoth Holdings

ATLANTA, Nov. 30, 2021 /PRNewswire/ — Mammoth Holdings, LLC (“Mammoth”), an Atlanta-based conveyor car wash operator, announced that Silverstar Car Wash (“Silverstar”), a fourteen-unit car wash operator with operations in South Dakota, North Dakota, Iowa, and Nebraska, has agreed to join the Mammoth organization. Silverstar’s ownership group made a significant equity investment in Mammoth.

Mammoth Holdings Appoints Chief Operating Officer And Chief People Officer

Mammoth Holdings Chairman and CEO David Hoffmann today announced two key appointments to his senior management team who will support the growth strategy for the Atlanta-based conveyor car wash operator. Effective immediately, Corey Joslin becomes Chief Operating Officer and Mark Hidle becomes Chief People Officer for Mammoth Holdings. Mammoth is the first car wash acquisition platform formed by industry insiders and is the seventh largest conveyor car wash operator in the United States with brands in 11 states.

Busy Bee Joins Mammoth Holdings

Mammoth Holdings, LLC (“Mammoth”), an Atlanta-based conveyor car wash operator, announced that Busy Bee Car Wash (“Busy Bee”), a three-unit car wash operator in Miami, FL, has agreed to join Mammoth. Busy Bee’s owner, Jim Mulholland, chose to invest into Mammoth’s equity.

STV Group, Inc., Agrees To Acquire CP&Y, Inc.

NEW YORK, Sept. 7, 2021 /PRNewswire/ — We are pleased to announce that STV Group, Inc., has agreed to acquire CP&Y, Inc. CP&Y is an employee-owned engineering, architectural, and field services consulting firm with a staff of over 375 professionals in Texas, Oklahoma, Colorado, Florida, and Virginia.

Bayer and Systems Oncology sign exclusive license agreement for investigational breast cancer treatment approach ERSO™

WHIPPANY, N.J., September 15, 2020 – Bayer has entered into an exclusive global license agreement with Systems Oncology, LLC, for ERSO™, a compound in pre-clinical development for metastatic Estrogen Receptor (ER) positive, breast cancer. ERSO is a small molecule activator of the Unfolded Protein Response (UPR) in ER-positive breast cancer cells. ERSO’s mechanism of action is a therapeutic approach being investigated in women with metastatic ER-positive breast cancer, an area where new therapies are urgently required.

Systems Oncology Receives Investment from The Pritzker Organization

Scottsdale, AZ – October 22, 2019 – Systems Oncology, LLC (“SO”) and The Pritzker Organization, LLC (“TPO”) announced today that Pritzker Family Business Interests advised by TPO have invested in the first closing of SO’s Series B round. The funding will be used to invest in both discovery research and pre-clinical development to evolve SO’s rapidly expanding pipeline of innovative cancer therapeutics.